HK1044711A1 - 包含胰島素敏化劑的藥物組合物 - Google Patents

包含胰島素敏化劑的藥物組合物

Info

Publication number
HK1044711A1
HK1044711A1 HK02105969.4A HK02105969A HK1044711A1 HK 1044711 A1 HK1044711 A1 HK 1044711A1 HK 02105969 A HK02105969 A HK 02105969A HK 1044711 A1 HK1044711 A1 HK 1044711A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
insulin sensitizer
sensitizer
insulin
pharmaceutical
Prior art date
Application number
HK02105969.4A
Other languages
English (en)
Chinese (zh)
Inventor
Sudo Katsuichi
Wada Yasuhiko
Sugiyama Yasuo
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of HK1044711A1 publication Critical patent/HK1044711A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK02105969.4A 1999-09-03 2002-08-15 包含胰島素敏化劑的藥物組合物 HK1044711A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25044399 1999-09-03
JP2000056021 2000-02-28
PCT/JP2000/005951 WO2001017513A2 (fr) 1999-09-03 2000-09-01 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
HK1044711A1 true HK1044711A1 (zh) 2002-11-01

Family

ID=26539777

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105969.4A HK1044711A1 (zh) 1999-09-03 2002-08-15 包含胰島素敏化劑的藥物組合物

Country Status (14)

Country Link
EP (1) EP1212090A2 (fr)
KR (1) KR20020063555A (fr)
CN (1) CN1372476A (fr)
AR (1) AR031674A1 (fr)
AU (1) AU6868000A (fr)
CA (1) CA2383946A1 (fr)
CO (1) CO5180632A1 (fr)
HK (1) HK1044711A1 (fr)
HU (1) HUP0203285A3 (fr)
NO (1) NO20021036L (fr)
PE (1) PE20010580A1 (fr)
PL (1) PL354295A1 (fr)
RU (1) RU2002108346A (fr)
WO (1) WO2001017513A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695716A2 (fr) * 2000-12-26 2006-08-30 Sankyo Company, Limited Compositions médicinales contenant un diuretique et un agent renforcant la résistance a l'insuline
WO2002080936A1 (fr) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs ppar
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
EP1514869A1 (fr) * 2002-06-12 2005-03-16 Sumitomo Pharmaceuticals Company, Limited Indole, indazole, et derive benzazole

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501722A (ja) * 1988-11-14 1992-03-26 ジ・アップジョン・カンパニー 抗―糖尿病、抗―肥満症および抗―アテローム性動脈硬化症薬として有用なα―アミノ―インドール―３―酢酸
DE69100282T3 (de) * 1990-02-09 2001-01-11 Pharmacia & Upjohn Co., Kalamazoo Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
CN1070477C (zh) * 1994-11-29 2001-09-05 大日本制药株式会社 吲哚衍生物

Also Published As

Publication number Publication date
NO20021036L (no) 2002-04-26
WO2001017513A3 (fr) 2001-09-20
PL354295A1 (en) 2004-01-12
KR20020063555A (ko) 2002-08-03
CA2383946A1 (fr) 2001-03-15
AU6868000A (en) 2001-04-10
HUP0203285A2 (hu) 2003-01-28
RU2002108346A (ru) 2003-11-20
HUP0203285A3 (en) 2003-02-28
AR031674A1 (es) 2003-10-01
WO2001017513A2 (fr) 2001-03-15
NO20021036D0 (no) 2002-03-01
CO5180632A1 (es) 2002-07-30
CN1372476A (zh) 2002-10-02
PE20010580A1 (es) 2001-05-25
EP1212090A2 (fr) 2002-06-12

Similar Documents

Publication Publication Date Title
PL351387A1 (en) Pharmaceutical composition
IL149224A0 (en) Hydrogen-driven drug dosage form
IL183972A0 (en) Pharmaceutical composition for modified release insulin sensitiser
ZA200000857B (en) Pharmaceutical composition.
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
GB0000710D0 (en) Drug combination
IL145632A0 (en) Pharmaceutical compounds
GB9916434D0 (en) Pharmaceutical compounds
GB9914255D0 (en) Pharmaceutical compounds
HK1044711A1 (zh) 包含胰島素敏化劑的藥物組合物
GB9903784D0 (en) Pharmaceutical compounds
GB9909154D0 (en) Pharmaceutical formulation
GB2373499B (en) Pharmaceutical compounds
GB9930160D0 (en) Drug delivery
GB9916413D0 (en) Pharmaceutical composition
GB9916210D0 (en) Pharmaceutical composition
HU9900587D0 (en) New pharmaceutical composition
GB9910671D0 (en) Improved pharmaceutical composition
GB9904304D0 (en) Drug delivery
GB9902593D0 (en) Drug combinations
GB9921064D0 (en) Drug combination
AUPP969899A0 (en) Pharmaceutical composition
AUPQ386599A0 (en) Pharmaceutical composition
GB9926434D0 (en) Pharmaceutical
GB9926437D0 (en) Pharmaceutical